Oxford BioMedica (GB:OXB) has released an update.
Oxford Biomedica has disclosed that Pippa Radcliffe, associated with Chief Innovation Officer Kyriacos Mitrophanous, exercised options for 839 shares at no cost and sold 274 shares at £3 each on June 25, 2024. The transactions took place on the London Stock Exchange, and are reported in compliance with the EU Market Abuse Regulation. This financial activity reflects insider movements within the cell and gene therapy firm.
For further insights into GB:OXB stock, check out TipRanks’ Stock Analysis page.
